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Abstract As genome sequencing technology advances, re-
search is needed to guide decision-making about what results
can or should be offered to patients in different clinical set-
tings. We conducted three focus groups with individuals who
had prior preconception genetic testing experience to explore
perceived advantages and disadvantages of genome sequenc-
ing for preconception carrier screening, compared to usual
care. Using a discussion guide, a trained qualitative moderator
facilitated the audio-recorded focus groups. Sixteen individ-
uals participated. Thematic analysis of transcripts started with
a grounded approach and subsequently focused on partici-
pants’ perceptions of the value of genetic information. Anal-
ysis uncovered two orientations toward genomic preconcep-
tion carrier screening: Bcertain^ individuals desiring all possi-
ble screening information; and Bhesitant^ individuals who
weremore cautious about its value. Participants revealed valu-
able information about barriers to screening: fear/anxiety
about results; concerns about the method of returning results;
concerns about screening necessity; and concerns about part-
ner participation. All participants recommended offering
choice to patients to enhance the value of screening and
reduce barriers. Overall, two groups of likely users of genome
sequencing for preconception carrier screening demonstrated
different perceptions of the advantages or disadvantages of
screening, suggesting tailored approaches to education, con-
sent, and counseling may be warranted with each group.
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Introduction
Compared to existing carrier screening technologies, genome
sequencing offers substantially more information for repro-
ductive decision-making. Mendelian recessive or x-linked
conditions, despite being individually rare, impact as many
as 2 % of live births. These conditions have an important
impact on the health of affected children and account for about
20 % of infant mortality and about 10 % of pediatric hospital-
izations (Costa et al. 1985; Kumar et al. 2001; Berry et al.
1987). Numerous conditions could be considered for carrier
screening, with more than 1000 known autosomal recessive or
x-linked conditions in the Online Mendelian Inheritance in
Man (OMIM) database. This substantial genetic heterogeneity
means that a large proportion of the genomemust be evaluated
to assess carrier status across all possible conditions. Howev-
er, current clinical practice is generally limited to evaluating a
small number of genes. Carrier screening is more widespread
for conditions like Cystic Fibrosis (CF), which is recommend-
ed to be offered to all couples considering pregnancy in the
U.S. (Grody et al. 2001; American College of Obstetricians
and Gynecologists Committee on Genetics 2011), beta-thal-
assemia, for which population screening programs have been
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implemented in countries with a higher prevalence such as
Greece, Italy, and Cyprus (Cao et al. 2002; Cousens et al.
2010), or Tay Sachs disease in the Ashkenazi Jewish popula-
tion (Kaback 2001). However, pre-conception carrier testing
is mostly offered only in specific situations that confer an
increased risk. It is typically offered to family members of
an identified carrier or affected individual, and members of
ethnic or racial groups known to have a higher prevalence of
a condition (ACOG Committee on Genetics 2009; American
College of Obstetricians and Gynecologists Committee on
Genetics 2011).
Commercial screening panels that incorporate tens or hun-
dreds of disorders have recently become available, but they
are usually limited to well-established gene variants. The yield
of carrier findings per person from current carrier testing
panels varies. One study found that 24 % of individuals were
carriers of at least one of 400 causal Mendelian variants
(Lazarin et al. 2013). Another study suggests that each person
is a carrier of 2 to 3 mutations for known disorders (Bell et al.
2011). At the genome scale, we may expect a relatively high
yield of findings per person because we can interrogate the
majority of the exome or genome (Biesecker andGreen 2014).
Additionally, genome sequencing can provide information on
incidental findings—conditions that would not impact a future
child’s health, but that impact the patient directly such as mu-
tations in BRCA1/2 that increase risk for hereditary breast and
ovarian cancer (Green et al. 2013; Kaphingst et al. 2015;
Regier et al. 2015; Bennette et al. 2013). Thus, carrier screen-
ing using genome sequencing (either whole genome or whole
exome, which we will refer to as Bgenomic carrier screening^)
could identify more mutations than panel screening and, as a
result, identify more couples at risk of bearing children affect-
ed by genetic conditions. Preconception carrier testing, which
represents a high proportion of the care delivered in medical
genetics, is a prime candidate for the use of genome sequenc-
ing. Further, carrier status is a potentially relevant secondary
finding whenever genome sequencing is used in adults of
reproductive age, regardless of why the sequencing was or-
dered. Despite the potential utility of genomic carrier screen-
ing, little is known about how patients react to findings from
such tests, and whether they find such testing acceptable, un-
derstandable, and useful to their family planning.
Such data are important because genomic carrier screening
lies at the intersection of two clinical activities that each raise
ethical concerns. Carrier testing raises questions about wheth-
er screening programs that are designed to decease the inci-
dence of genetic diseases will pressure adults to accept testing
that they really do not want, and if such programs send mes-
sages that are harmful to the disease communities for which
testing is targeted (Wilfond and Thomson 2000). Carrier test-
ing after conception is controversial because of strongly held
beliefs regarding whether it is ethical to terminate a pregnancy.
Genomic sequencing raises questions about adverse impacts
on people who receive information that may be difficult to
interpret, which can be confusing, and may result in unneces-
sary clinical interventions (Wade et al. 2013; Wilfond and
Goddard 2015). Obtaining data about the experience of pa-
tients can help address the veracity of these concerns, and aid
in developing approaches to address them. To improve our
understanding of the utility of genomic carrier screening, we
explored patients’ perceptions of its advantages and disadvan-
tages of this service (as compared to usual clinical care)
through a series of focus groups. This research was conducted
as part of the National Human Genome Research Institute
(NHGRI) Clinical Sequencing Exploratory Research
(CSER) consortium. As part of this consortium, we are cur-
rently conducting a research study on the implementation of
genome sequencing for couples seeking preconception carrier
testing.
Methods
Study Site and Background Kaiser Permanente Northwest
(KPNW) is an integrated health care delivery system that
serves approximately 500,000 health plan members in the
Portland, Oregon metropolitan area. The single most common
genetic or genomic application used in practice today at
KPNW is carrier testing for CF, which is routinely offered to
women who become pregnant or are planning a pregnancy,
with about 3900 tests per year. About 14 % of CF tests are for
couples seeking pre-conception testing. Women who receive
pre-conception carrier screening tend to be older than the av-
erage for pregnant women (34 years vs. 25 years), and are
likely to receive CF testing as part of an encounter to address
questions about infertility.
Sampling and Recruitment As part of a clinical trial of ge-
nomic preconception carrier screening at KPNW, we conduct-
ed three focus groups (Morgan 1998) to understand what fac-
tors hinder or facilitate such screening. We used data extracted
from the electronic medical record (EMR) to identify women
(ages 18–50) with current health plan membership, and who
had preconception carrier testing in the past 5 years. A recruit-
ment list was generated and sorted by zip code to identify 100
participants living near each of the three focus group loca-
tions. We attempted to increase the diversity of perspectives
and experiences represented in the focus groups in several
ways. First, sessions were intentionally held in clinics located
within different socio-demographic constituencies (inner ur-
ban; suburban; and mixed urban/suburban). Second, we
oversampled minority group members to compensate for lim-
ited population diversity in the metropolitan area by utilizing
minority identifiers in the EMR (African–American and
Asian) and concentrated initial calls for members in target
zip codes.
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Data Collection A discussion guide was iteratively devel-
oped by the research team with a final version approved by
the project’s lead qualitative researcher (CM). The guide
consisted of overarching questions, presented in an open-
ended fashion, followed by prompts for specific feedback on
certain issues (Online Resource 1). The focus group leader
(CM) provided an orientation to genome sequencing and car-
rier screening at the beginning of each session through a brief
slide presentation (Online Resource 2). Slides defined geno-
mic carrier screening, standard carrier testing, and incidental
findings (receiving results about oneself), and explained how
genome sequencing differs from what has been offered tradi-
tionally in the health plan. The discussion also entailed careful
review of a draft consent form for genomic carrier screening;
many terms and concepts were clarified in that discussion.
Additionally, a content expert—either a medical geneticist
(JR) or a genetics researcher (KG), was present at each session
to help clarify concepts and answer questions from partici-
pants. Discussion topics included: prior experience with ge-
netic testing; reasons participants would/would not choose to
have genomic carrier screening; awareness/understanding
about the risks and benefits of screening; reactions to receiv-
ing incidental findings (IF); and preferences for returning re-
sults. All sessions were audio-recorded for verbatim transcrip-
tion. Participants were consented, and all focus group proce-
dures and materials were approved by the Institutional Review
Board at KPNW.
Data Analysis Qualitative data analysis was aided by the use
of ATLAS.ti 5.0 software (Scientific Software Development
1997) for coding data and generating reports of coded text for
analysis. We engaged in a two-stage thematic analysis,
starting with a grounded, open-coding approach (Strauss and
Corbin 2008), followed by a more focused analysis based on
participants’ perceptions of the value of genetic information.
For the grounded approach, we first developed a coding dic-
tionary based on the guide, review of the transcripts, and dis-
cussion with the qualitative study team (CM, BW, JR, TK,
KG, JS, and JD). Transcribed interviews were coded by
trained staff (JS), by marking passages of text with phrases
(e.g. codes) indicating content. Using the query functions of
ATLAS.ti, reports of coded text were generated for review and
further analysis, divided both by codes (e.g., barriers to
screening) and focus group session (e.g., session one).
During this review process, we noticed that more than half
of the participants across the focus groups were high informa-
tion seekers, while others were less so. We determined it
would be revealing to distill differences among strong
information-seekers and those who were more cautious about
the information they wanted to receive, so that we could better
understand the range of barriers and facilitators to obtaining
preconception genomic carrier screening. Thus for the second
stage of analysis, each transcript was carefully re-reviewed,
and participants were identified as either being Bcertain^ (e.g.,
made clear statements about wanting to know/seek out this
information) or Bhesitant^ (e.g., made clear statements about
feeling unsure they would want to know/seek out this infor-
mation). Participants distinctly fell into one of these two ori-
entations, with none being ambiguous based on their com-
ments. Thematic code reports were re-generated and reviewed
for each of these two orientations. We applied the same ap-
proach when reviewing focus group discussions about receiv-
ing IFs.While taking this analytical approach, we continued to
review coding reports through an ongoing, inductive process,
resulting in refined themes (Patton 2002; Wolcott 1994; Ber-
nard and Ryan 2010). A trained and experienced expert in
qualitative analysis who did not conduct the focus groups
(JS) led the analysis process, with input and guidance from
the focus group moderator and research team. This allowed
for both an outsider (JS) and insider (remaining listed authors)
review of the focus group data, as refined themes were con-
tinually shared with the research team and clinical staff in an
ongoing process until the group reached consensus on
interpretation.
Results
Recruitment Results and Descriptions of Participants We
made 287 recruitment call attempts, and reached 109 (38 %)
individuals. Of those, 81 (74 %) declined participation (e.g.,
busy/unavailable=61; not interested =12). The remaining 28
individuals were booked into the three focus groups; 12 did
not show up. Overall, 16 individuals participated across the
three sessions. Table 1 describes their characteristics. Focus
group 1 (FG1) had six participants, five female and one male,
with a mean age of 30. The male attendee was an un-recruited
spouse of a participant who came to the group (consented and
participated). Focus group 2 (FG2) had six female participants
with a mean age of 31, and focus group 3 (FG3) had four
female participants with a mean age of 28. A majority of
participants described having many years of membership with
the health plan, with most participants (n=7) reporting some-
where between 5 years and 20 years, and several (n=5) indi-
cating a Blifetime^ of 21 years or more. A few respondents
described being newer to the health plan, having four or less
membership years. Despite our efforts to invite minority par-
ticipants, all participants were Caucasian.
Prior History and Experience with Genetic Testing As de-
scribed above, we intentionally recruited women who ap-
peared to have some prior preconception genetic testing expe-
rience within the health plan. During the beginning of the
session, we asked participants to share their Bstory^ of how
and why they obtained prior preconception testing to help
develop rapport during the session and provide a frame of
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reference for the discussion about genomic carrier screening
in our current study. The majority of participants (n=12) in-
dicated the conversation about obtaining testing was initiated
by either their primary care provider or obstetrician. Partici-
pants attributed the conversation originating from their pro-
vider often due to the participant’s age, current health status,
prior fertility challenges, or health/family history.
I was talking with the nurse practitioner in the OB/GYN
clinic—I had had a miscarriage about a year before. And
so she recommended it. So my husband and I made the
decision, since we had the miscarriage, and we won-
dered if there was something causing that, that had to
do with our genetics.
Three participants described initiating the conversation
about preconception testing with their provider, actively seek-
ing out this information as part of their family planning ap-
proach. For most focus group participants (n=10), the testing
occurred before the member became pregnant in an effort to
help with pregnancy planning and fertility challenges. How-
ever, about one-third (n=5) described the testing occurring
during their pregnancy due to their own or their partners’
health history, current health status, or family heritage. Partic-
ipants made reference to receiving testing for such things as
Down Syndrome, Cystic Fibrosis, and Tay-Sachs disease.
I am fifteen weeks pregnant, and this is my first preg-
nancy. And my husband’s sister had a Down’s pregnan-
cy that they terminated. I don’t know for sure, but I don’t
think if it weren’t for that I would have opted for genetic
screening… I figure it was a good thing to do. And
really, the reason we did was because that would affect
our decision as far as moving forward.
Due to time constraints within the focus group session and
a desire to focus the majority of the discussion on reactions to
genomic carrier screening, we did not systematically explore
the outcome of these prior preconception genetic testing ex-
periences, nor did participants volunteer this information. We
did, however, ask participants to reflect on any barriers or
concerns with their prior preconception testing experience.
The most frequently described concern was how the testing
added another layer of stress to an already anxiety provoking
experience of trying to become pregnant or a first time mother
(n=6). This is exemplified in an exchange among participants
in one of the focus groups.
P#2: I feel like everything about impending motherhood
is anxiety provoking. [non-verbal: All agree with head
nodding or saying Byeah^ over each other]…
P#4: Especially when you’re waiting for those [genetic
screening] results. What are they going to say?
Other concerns expressed less frequently included: having
a non-supportive or non-participatory partner in the testing
process (n=2); being uncomfortable with anything perceived
as invasive (n=2); having a negative reaction to some of the
genetic testing terminology, such as the word Bmutation^ (n=
2); expense due to health plan not covering desired tests (n=
1); and feeling overloaded with information (n=1).
Is Genomic Carrier ScreeningWorth Knowing? Following
the brief discussion about participants’ prior genetic testing
experience, the moderator described the current study about
genomic carrier screening, how this differs from the usual
clinical care participants had experienced previously (Online
Resource 2), and solicited participants’ reactions. Our analysis
of the ensuing discussion centered on an overarching theme
that divided focus group participants’ orientation towards ge-
nomic carrier screening: Is it Bworth knowing^ the results of
such tests? We found that participants could be characterized
as having two basic orientations toward the value of this
screening: those Bcertain^ about obtaining screening (n=10)
represented across all three focus group sessions, and those
more Bhesitant^ (n=6), represented by three participants each
in FG1 and FG2. Review of comments made by Bcertain^ and
Bhesitant^ participants revealed differing descriptive charac-
teristics of these two groups as highlighted in Table 2, along
with illustrative quotes.
Table 1 Characteristics of focus group participants (n=16)
Focus Group (FG) Session Gender Age Years as Health-plan member
F M Mean Range < or=4 years 5–10 years 11–20 years 21+ years
FG 1 (n=6) 5 1a 30 21–37 0 1 2 3
FG 2b (n=6) 6 0 31 28–37 2 1 1 1
FG 3 (n=4) 4 0 28 25–31 1 2 0 1
All participants were Caucasian
aMale attendee in FG1 was un-recruited spouse of a participant who came to group, was consented and participated
b one participant in FG2 came in later so we did not obtain information on age or years at KPNW
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Participants who were certain considered genomic carrier
screening Bworth knowing^ because for them, Bknowledge is
power.^ They described how information derived from the
screening could reduce anxiety and provide a sense of control
that would enhance family planning decisions. They claimed
that test results could help them prepare for the possibility that
their offspring may have a genetic condition, including taking
such actions as: engaging in supportive discussions with their
partner, health care providers, or others; changing how they
approach their health and lifestyle choices (e.g. nutrition, exer-
cise) for themselves and their family; researching the condition
and possible future treatments/cures; and possibly considering
termination of a pregnancy. Additionally, these focus group
members typically desired to know all possible results from
genome sequencing, including adult onset conditions. This de-
sire to have all possible results was driven by the belief that
Bknowing^ the information now may assist in searching for
potential cures or treatments that could arise in future years.
In contrast, participants who were hesitant about the value
of genomic carrier screening were guided primarily by the
belief that too much knowledge can foster uncertainty and
stress. Reasons included: it would not likely change their
choice or decision to start a family; it would be a waste of
time, money, resources or emotions over something that may
not happen; screening just because science or the health care
system allows for it may not outweigh the stress of obtaining
the information; and it interferes with the Bsacred^ and natural
experience of becoming pregnant or being a parent. These
participants also were more likely to want a more limited set
of result categories if they did decide to have genomic carrier
screening. For example, they did not think it was important or
necessary to learn about later adult onset results because the
potential impact of this knowledge would be too far out in the
future, and the scientific knowledge about such conditions and
their treatment could change by the time any affected off-
spring reached adulthood.
Ba r r i e r s t o S e e k i n g ou t G en om i c Ca r r i e r
Screening Participants described four main barriers, with dif-
ferent orientations toward these barriers among the certain and
Table 2 Is genomic carrier screening worth knowing? Differences between Bcertain^ and Bhesitant^ participants (n=16)
Certain (n=10)
(FG1=3; FG2=3; FG3=4)
Worth knowing as knowledge is power
Hesitant (n=6)
(FG1=3; FG2=3; FG3=0)
Not sure worth knowing as knowledge fosters uncertainty & stress
Reasons worth knowing Reasons may not be worth knowing
• Information and knowledge gives a sense of control, lessens anxiety
and helps with decision-making
Illustrative quote: BI want the information. I want the facts, because I
can deal with things better if I have the facts… I would feel more in
control, in a situation where you could feel completely out of control.^
• Information won’t change choice to start a family (e.g. have children)
Illustrative quote: BFor us, it wouldn’t be serious enough that we would
choose an abortion. So therefore it doesn’t really matter what the test
would say.^
•May help parent engage in prevention activities and change how approach
health for self and family (diet, exercise, lifestyle & health choices)
Illustrative quote: BI’d want to know too. I mean maybe it will be a
motivation to eat more healthfully and exercise a bit more, take
supplements… [Chuckles] I mean, we all should. But I would definitely
want to know.^
• Do not want to invest time, money, resources and emotions in something
that may not happen
Illustrative quote: BI’m like what is the value in this, not just for me but like
bigger picture? And I don’t know that I want to invest that much time
and money and other resources into more than I need… is it worth
knowing?^
• May help parent prepare for the possibility of the condition (support/
conversations with partner; terminate pregnancy or not; plan as best
can for future possibilities)
Illustrative quote: BHe and I would want to know…even if I couldn’t
prevent it from happening…so we could be as prepared to deal with it as
possible.^
• Stress of obtaining screening may not be worth knowing just because
science or healthcare system can offer it
Illustrative quote: BWhat if it [genomic carrier testing] turns out positive,
you still don’t know for certain…I just think it’s very stress inducing.
Your partner has to get tested. And even then, your child still might not
get this disease. So you might be doing all of this testing and, again, all
this stress and your child could be perfectly healthy.^
•May be a cure or treatment in the future so important to know information
so can be researching/looking for these options
Illustrative quote: BI like to research… I just want to know and be prepared
for the possibilities. So for me, knowing and being able to investigate
more about specific areas that I could be dealing with…^
• Feels like it interferes with the Bsacred^ experience of pregnancy and
becoming a parent / prefer more holistic approaches
Illustrative quote: BI’m really conflicted, because pregnancy and child
rearing is a timeless thing. And it’s become this medical thing… I don’t
think that it [genomic carrier testing] should become the norm.^
• Late adult onset conditions may be equally important to learn about in
case cure or treatments arise over the years
Illustrative quote: I would want to know [late adult onset conditions] so that
when my child is ready to have that conversation, you know, that’s when
there will be cures for these things…I want you to know so that I can be
listening to the research that says, ‘we’ve just found a cure to [such and
such]’…I could prepare my child to be on the lookout.^
• Late adult onset conditions seem less important or necessary to know
about (too far out in future; information could be wrong; science could
change)
Illustrative quote: BSo if you tell me that my kid could have something
when he’s sixty, chances are that something is going to happen that could
very drastically change the course of medicine in the next sixty years. So
I think it [knowing late adult onset conditions] becomes irrelevant.^
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hesitant participants, summarized in Table 3, along with illus-
trative quotes. The most commonly cited barrier (n=9) was
fear and anxiety about what may be discovered. The hesitant
participants stated that actively choosing to not know some-
thing can be easier than coping with the stress of knowing it,
especially when that information is perceived as uncertain,
undesirable, or scary. They were also afraid that knowledge
of screening results could interfere with life plans. Thus, ac-
tively choosing to not obtain genomic carrier screening was
described as creating a sense of freedom to proceed with fam-
ily planning goals unencumbered by the burden of knowing
potentially difficult information about future offspring. Alter-
natively, the certain participants expressed fear and anxiety
about findings being incomplete or not clear enough to guide
family planning or care decisions for future offspring. Addi-
tionally, certain participants were anxious that they may have
insufficient education and knowledge to fully understand their
reproductive and family planning choices and options once
they learned about results.
The second most commonly mentioned barrier (n=7) re-
lated to how genomic carrier screening results are shared.
The certain participants wanted to receive all of the result
information, possibly within one (rather than multiple) visits,
and were not comfortable with the fact that researchers and/or
clinicians might have more information than what would be
revealed to patients (such as non-actionable findings, or vari-
ants of unknown significance). Hesitant participants were con-
cerned about the perceived Bbleak^ discussion of possible
outcomes that would be part of the consent process for such
screening or the terminology used to convey such informa-
tion. Hesitant participants demonstrated more sensitivity to
the language and terminology used in describing genomic
carrier screening, reacting negatively to terms like
Bmutation,^ Bdeath,^ or Bmedically involved.^ Hesitant





Fear and anxiety of what will find out
• Fear/anxiety that not enough certain or detailed information will be
found out to guide decisions (incomplete findings)
• Coping with the fear and anxiety of genome-scale carrier testing results
that could be difficult or emotional is much harder than coping with not
ever having this knowledge
• Concern lack of own knowledge about what genomic carrier screening
is may lead to not fully understanding choices and options
Illustrative quote: BGoing into this, I’m pretty young and pretty new to
this particular world. I want as much information as possible, because
with this [testing] that we’re talking about there’s a lot that can go wrong.
And as parents, or somebody who wants to be a parent, you want to be as
informed as possible.^
• Fear that knowledge from genomic carrier screening may interfere with
family planning dreams and goals
Illustrative quote: BIf you don’t know, it’s a lot easier to go along in
ignorance, and just let whatever happens happen…I think fear is a big
motivator to either do something or to not do something.^
Concerns of how and when results are shared
• Not being given all of the result information at once (e.g. in one visit)
fosters stress/resistance to doing genomic carrier screening
Illustrative quote: BAnd then in getting this testing [you] actually do a
whole lot of waiting… So waiting and then [potentially] having multiple
appointments… I can see how that could make you upset or even more
stressed out.^
•Waiting a long time for results fosters fear, anxiety and possible resistance
to doing genomic carrier screening
• Potentially being treated as a ‘number’ or ‘percent’ rather than a human
being creates resistance to screening
Illustrative quote: BI’m thinking about having a baby. It could be two to
three months before I know these results… And I could see for me, that
causing a lot of anxiety - all of a sudden I have to start postponing
things.^
Uncertainty whether a clear need or rationale exists for testing
• Fascination and/or trust in science/technology and what it can provide
overshadows concerns as to whether a clear need exists or not to seek out
genomic carrier screening
Illustrative quote: BAs far as I know, I don’t have anything in my family
that would be a cause for alarm for…and I love studies for any genetic
research.^
• If no personal medical history or family history on either side of partner/
family then likely would choose not to do genomic carrier screening
• Put trust in higher power/ less trust in medical technology or interference
Illustrative quote: BI wouldn’t do it unless I had some history of something
I was specifically wanting to know more and feel more confident
about…But for me, it’s too much information… It’d drive me crazy. I’d
be worried about it too much.^
Lack of partner participation
• Resistance to engage in genomic carrier screening if have incomplete data
due to lack of partner involvement
Illustrative quote: BI would be concerned how I interpreted the results if
you haven’t [tested] my husband…you need to think about those X-
chromosome types of conditions.^
•May create tension within partnership if lack of mutual agreement exists
on whether to engage in genomic carrier screening
Illustrative quote: BAnd why would you want that person to go through it
alone? Because what if one has reservations and the other doesn’t? Does
one unilaterally get to decide, okay, I’m doing this? And then, if you
don’t agree you don’t have the do the second part. But then that creates a
potential fight later on [when female results come in]…^
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participants described how terms like these can foster a sig-
nificant emotional reaction of fear or anger, setting one up to
potentially misunderstand genomic carrier screening options
and/or results. They also objected to waiting a long time for
their genome sequencing results. Within the context of our
study, for which participants were reacting the return of results
was described to be approximately 12 weeks. This wait-time
may be less in other contexts.
Two other barriers were cited by about one-third (n=5)
of the participants. One barrier was lack of a clear need
or rationale for screening. Hesitant participants stated
that they would likely not obtain it if they or their partner
had no personal medical or family history that would in-
crease their risk for having offspring affected by a genetic
condition. Additionally, some of these participants cited
they would prefer to put their trust in a Bhigher power^
rather than in science or interference by medical technol-
ogy. On the other hand, certain participants were curious
about and trusting in what science and medical technolo-
gy can provide. Another barrier was lack of partner
participation. Hesitant participants mentioned concerns
that lack of mutual agreement to be screened could foster
tension within their partner relationship, while certain par-
ticipants were more concerned with having incomplete
data or results to base decisions on due to lack of partner
involvement.
Factors that Facilitate Genomic Carrier Screening While
much of the discussion focused on barriers to or concerns
about obtaining genomic carrier screening, participants also
shared factors that would motivate them to obtain screening.
The primary motivator for the majority of participants was a
desire to do Beverything possible^ to protect the health of their
offspring. This was strongly expressed by both certain and
hesitant participants. They saw value in obtaining the screen-
ing so they would know what to expect and be better prepared
for themselves and their offspring. Also, they felt having this
information before conception could help explain or decrease
pregnancy related complications and possibly prevent
miscarriages.
Because my biggest concern would be, if I decide I
don’t want to find out about it, but the child has it and
I don’t know, and then I do something wrong that causes
a problem… So I would want to know, at least somehow
to be able to help and provide that child the best care
possible.
Certain and hesitant participants revealed some subtle
differences in their motivation for screening. Certain par-
ticipants discussed the benefit of being both financially
and emotionally prepared early on, allowing them to be
more capable to offer support and coping assistance to
help their partner and affected offspring. Hesitant partici-
pants were more motivated to obtain testing as they be-
lieve the results could help them create a Bnormal life^ for
their affected offspring and allow the child to be a part of
society in some of the same ways as children who do not
have the genetic condition.
Choices are Essential A key recommendation strongly
expressed by all participants during the discussions was
the importance of providing choice at every level of of-
fering genomic carrier screening—including choice in
whether to seek out this information, the type and quan-
tity of results being shared, how and when to receive the
results, and from whom they would want to receive the
results and/or have follow up conversations. Both certain
and hesitant participants described how offering choice is
paramount to making genomic carrier screening Bworth
knowing^ since people will bring their unique range of
emotions, expectations, and prior experiences into their
decision-making. Participants described how offering
clear patient choice at multiple levels can make one more
open to obtaining and knowing results from genomic car-
rier screening, and facilitates greater acceptance of receiv-
ing potentially difficult information. Participants saw pro-
viding choice as a means to decrease fear and anxiety
about obtaining screening or learning results because
choice fosters a sense of control about what and how
much one may want to know. As one participant
summarized:
I think as much as you can, cater to each individual’s
needs…as many options as you can give them about
finding out about results or how to communicate with
providers about it. Just be really open to everyone’s
unique needs in terms of how they arrive at deciding
to get genetic testing.
Discussion
Preconception genomic carrier screening may strengthen
reproductive autonomy and informed decision-making
compared with prenatal screening or even existing pre-
conception panel tests because it maximizes the number
of conditions tested and the reproductive options available
to couples at higher risk of bearing affected offspring
(Modra et al. 2010; Borry et al. 2011). However, several
opinions exist within the field about whether or how to
deliver such screening, including which genome sequenc-
ing results should be returned to patients (Burke et al.
2001; Ravitsky and Wilfond 2006). With the rapid ad-
vances in genome sequencing technology and the
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increasing commercial availability of genomic tests, addi-
tional research is needed to guide decision-making about
what types of information can or should be offered to
patients, and to elucidate how patients understand and
prioritize this information (Bollinger et al. 2012; Hosli
et al. 2008).
We explored barriers, facilitators, and the perceived utility
of preconception genomic carrier screening in focus groups
with individuals of child-bearing age with prior genetic testing
experience. Our analysis revealed two types of likely orienta-
tions toward preconception genomic carrier screening—cer-
tain individuals who desire all the information possible from
genomic carrier screening because this knowledge provides a
sense of control in their family planning decisions; and hesi-
tant individuals who are more cautious as the knowledge ob-
tained could possibly be anxiety-provoking, would not likely
change their family planning decisions, and potentially
Bmedicalizes^ the natural experience of pregnancy and moth-
erhood. Analysis revealed that these two types of orientations
have slightly different perspectives on four participant-
identified barriers to screening: fear and anxiety about results;
concerns about the method of returning results; concerns
about the necessity for screening; and concerns about male
partner participation in screening. All participants overwhelm-
ingly recommended offering choice to patients as a way to
enhance the value of and reduce barriers to screening.
Allowing patients and their partners to choose what they want
to find out, and how, may allay concerns and enhance benefits
of screening among both certain and hesitant individuals. The-
se focus group findings may help address the broader ethical
and clinical question regarding the utility of providing this
type of screening (Burke et al. 2010; Burke et al. 2001;
Remennick 2006), helping to negotiate a balance between
potential benefits and harms.
Our focus group findings support and expand upon recom-
mendations found in the literature. The American College of
Medical Genetics and Genomics (ACMG) recommends
prenatal/preconception expanded carrier screening processes
that uphold patient choice, autonomy, and lack of harm
(Grody et al. 2013). Another qualitative study about carrier
screening for fragile X syndrome (FXS) also found the Bright
to choose^ testing and results to be a unifying theme across
stakeholder groups (providers, pregnant women, and general
public) (Archibald et al. 2013). Our focus group participants
echoed these sentiments. In describing negative aspects of
their previous experience with genetic testing as stressful, un-
necessarily invasive, or causing conflict with their partners, it
seems that the context of such testing, namely health care
utilization associated with trying to become pregnant, frames
women’s orientation to preconception genetic testing, whether
it is traditional or genome scale testing.
By analyzing barriers and facilitators to genomic carrier
screening from the perspectives of certain/hesitant
orientations, we demonstrate variability in the perceived value
of such information that is also found in other studies. An
exploration of informed decision-making for carrier screening
for FXS in non-pregnant women (Metcalfe et al. 2008) found
that the most common reason to decline FXS testing was
concern about knowing Bworrisome^ information that would
likely not alter reproductive plans; this was similar to what we
found among our hesitant participants. In the case of screening
for CF, research suggests that the perceived value of informa-
tion shapes decisions about testing. Prenatal and preconcep-
tion carrier screening for CF was introduced into routine ob-
stetric practice in 2001 (Grody et al. 2001). There has been
variable uptake: some of the variability is related to women’s
values and interest in the information.
Studies of FXS and CF have described decision-making
processes relating to preconception carrier screening, some-
thing we did not explore in our focus groups. Participants in
our focus groups were discussing hypothetical situations, not
making actual screening decisions, limiting our understanding
of decision making related to genomic carrier screening. In the
case of FXS, women who chose to test or not revealed a two-
step decision-making process, with the first phase focusing on
issues of relevancy (e.g. reproductive stage of life); followed
by a stage of deliberation in which one may be influenced by
factors such as valuing the knowledge from testing, perception
of risk, and logistical issues (Archibald et al. 2009). In the case
of CF, decision-making has been shown to vary by the context
of testing (Grody et al. 2001; Ioannou et al. 2014)—whether it
is presented prenatally, recommended by a provider, or re-
quires the woman to actively seek it out (Modra et al. 2010).
Future research, including our ongoing trial of preconception
carrier screening, should explore whether decision making
processes for genomic carrier screening resemble other carrier
testing or screening scenarios, in which relevancy and the
timing of decisions play an important role.
Ultimately, tailored approaches to offering genomic carrier
screening could be developed to address differences in pa-
tients’ certainty regarding the utility of such screening. The
differences in how certain and hesitant participants talked
about barriers indicates that educational materials, consent
documents, genetic counseling and primary care provider
talking points could address and/or be tailored to these differ-
ent orientations. Understanding the differences between cer-
tain and hesitant individuals can provide guidance in both
creating materials and in training providers in how to best
offer and communicate about genomic carrier screening.
Finally, we looked at comments of hesitant and certain
participants regarding incidental findings and did not find
clear differences between the two groups. This may mean that
a person’s perceptions about the utility of preconception ge-
nomic carrier screening may not be generalizable to other
types of genomic screening. Distinguishing the differences
in barriers and facilitators for genetic screening when it
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provides information about one’s own health versus the health
of one’s offspring is an area for future exploration.
Limitations
Our study has some limitations. The small sample size and
lack of minority participants may limit the use of our findings
as possible guidance for others to consider. Our relatively low
recruitment rate may have resulted in some selection bias
among focus group participants, with more representation
from participants who were enthusiastic about genomic pre-
conception screening. Within the dynamics of a focus group
discussion, some participants may not always express their
opinion when it differs from others; and others may dominate
discussions with their style of communication. There is a pos-
sibility that the opinions of those categorized as hesitant may
be understated because they were a minority of the partici-
pants, while the certain participants may have been more vo-
cally dominant. Additionally, those categorized as hesitant
were present in only two of the focus groups. However, we
employed several strategies to improve the credibility and
trustworthiness of our data (Patton 2002; Morgan 1998;
Denzin and Lincoln 2011), including using a trained focus
group facilitator experienced in managing group dynamics;
employing an interview guide to assure consistency of data
collection across focus group sessions; using a formal, team-
based approach to analysis that included transcription, coding,
and multiple reviews of summarized themes; and reviewing
our findings with project and health plan staff to get a sense of
the Bface^ validity of our data as it compares to what they hear
from patients.
Conclusion
Advances in genome sequencing technology create great po-
tential for informing and improving reproductive decision
making; however, in making this screening available we need
to understand both clinical utility and ethical considerations
from the viewpoints of multiple stakeholders. This paper
looks at patients’ perspectives through a series of focus
groups. We found two distinct types of potential users of pre-
conception genomic carrier screening who demonstrated dif-
ferences in perceived advantages or disadvantages of screen-
ing. Our findings suggest that tailored approaches to educa-
tion, consent and counseling may be warranted with each
group, and may help foster informed decision-making about
whether to obtain testing. Given that our focus groups mem-
bers were reacting to a hypothetical scenario and were not
participants within our current clinical trial, our results are
most indicative of patients’ stance toward preconception ge-
nomic screening before the consent process, which involves
learning about the potential benefits and harms of testing. In
that context, participants in the certain group displayed what
could be described as over-confidence about the value of ge-
nomic information. This over-confidence warrants clear and
consistent communication about the limits of the technology,
current scientific knowledge, and some of the potential down-
sides of testing. Hesitant participants shared the need for ma-
terials and talking points to be sensitive to terminology that is
potentially confusing or anxiety-provoking; a desire to poten-
tially avoid results pertaining to severe/life threatening out-
comes or conditions impacting infancy/early childhood; sug-
gestions to avoid being overwhelmed with Btoo much infor-
mation^ by sharing pre-consent and potential result informa-
tion over multiple visits rather than just one visit; and a need
for coordination of care across multiple providers (Ob/Gyn;
PCP; genetic counselor) that is consistently and clearly docu-
mented within the medical chart so that the responsibility of
any follow-up actions does not solely fall upon the patient,
who may feel emotionally burdened by the knowledge of
screening or related results.
Within our current clinical trial of preconception genomic
carrier screening, we are continuing to gain knowledge about
how to tailor services so that testing can be delivered in a way
that responds to patient values and orientation toward geno-
mic information. We are also collecting information about
why patients decline to participate in our trial. These data will
result in concrete suggestions about tailoring information and
services at different phases of clinical care, including offering
services, informed-decision making about testing, return of
results, and guidance about future steps after obtaining results.
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